- Home
- VERU vs SAVA Comparison
VERU vs SAVA Comparison
Compare VERU & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- SAVA
- Stock Information
- Founded
- VERU 1971
- SAVA 1998
- Country
- VERU United States
- SAVA United States
- Employees
- VERU N/A
- SAVA N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- VERU Health Care
- SAVA Health Care
- Exchange
- VERU Nasdaq
- SAVA Nasdaq
- Market Cap
- VERU 85.5M
- SAVA 70.5M
- IPO Year
- VERU 1990
- SAVA N/A
- Fundamental
- Price
- VERU $0.49
- SAVA $2.21
- Analyst Decision
- VERU Strong Buy
- SAVA Buy
- Analyst Count
- VERU 2
- SAVA 2
- Target Price
- VERU $4.00
- SAVA $54.50
- AVG Volume (30 Days)
- VERU 1.4M
- SAVA 882.8K
- Earning Date
- VERU 08-07-2025
- SAVA 08-07-2025
- Dividend Yield
- VERU N/A
- SAVA N/A
- EPS Growth
- VERU N/A
- SAVA N/A
- EPS
- VERU N/A
- SAVA N/A
- Revenue
- VERU $16,886,419.00
- SAVA N/A
- Revenue This Year
- VERU N/A
- SAVA N/A
- Revenue Next Year
- VERU N/A
- SAVA N/A
- P/E Ratio
- VERU N/A
- SAVA N/A
- Revenue Growth
- VERU 134.43
- SAVA N/A
- 52 Week Low
- VERU $0.45
- SAVA $1.15
- 52 Week High
- VERU $1.42
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- VERU 34.85
- SAVA 50.57
- Support Level
- VERU $0.57
- SAVA $2.33
- Resistance Level
- VERU $0.61
- SAVA $2.72
- Average True Range (ATR)
- VERU 0.04
- SAVA 0.16
- MACD
- VERU -0.01
- SAVA 0.01
- Stochastic Oscillator
- VERU 0.13
- SAVA 25.00
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.